1
/
of
1
Elabscience
SKU:E-CL-H0902
Human NF-κB p65(Nuclear Factor Kappa B p65) CLIA Kit
Human NF-κB p65(Nuclear Factor Kappa B p65) CLIA Kit
Regular price
$682.00 USD
Regular price
Sale price
$682.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the HUMAN NF-ΚB P65 (Nuclear Factor Kappa B P65) CLIA Kit, a cutting-edge solution designed to facilitate accurate and efficient analysis of NF-ΚB P65 levels in human samples. This advanced kit is meticulously crafted to meet the highest standards of quality and reliability, ensuring precise and reproducible results.
The HUMAN NF-ΚB P65 CLIA Kit employs a Chemiluminescent Immunoassay (CLIA) technique, which enables sensitive and specific detection of NF-ΚB P65 in a variety of biological specimens. With its exceptional sensitivity and broad dynamic range, this kit empowers researchers and clinicians to explore the intricate mechanisms of NF-ΚB P65 activation and its implications in various physiological and pathological processes.
This comprehensive kit includes all the necessary components for a seamless workflow, including pre-coated microplates, assay buffers, detection reagents, and a detailed protocol. The user-friendly nature of this kit allows for effortless implementation, making it suitable for both experienced laboratory professionals and novices alike.
The HUMAN NF-ΚB P65 CLIA Kit offers numerous advantages, such as its high specificity, minimal cross-reactivity, and low background noise. These features ensure the utmost accuracy and reliability in quantifying NF-ΚB P65 levels, enabling researchers to draw meaningful conclusions from their experimental data.
Furthermore, this CLIA kit exhibits excellent precision and reproducibility, minimizing inter-assay and intra-assay variations. Its robust performance guarantees consistent and dependable results, facilitating the progress of scientific investigations and clinical studies.
In summary, the HUMAN NF-ΚB P65 CLIA Kit represents a state-of-the-art solution for the quantification of NF-ΚB P65 in human samples. With its exceptional sensitivity, specificity, and reliability, this kit empowers researchers and clinicians to unravel the intricate role of NF-ΚB P65 in various biological processes, ultimately contributing to advancements in biomedical research and healthcare.
The HUMAN NF-ΚB P65 CLIA Kit employs a Chemiluminescent Immunoassay (CLIA) technique, which enables sensitive and specific detection of NF-ΚB P65 in a variety of biological specimens. With its exceptional sensitivity and broad dynamic range, this kit empowers researchers and clinicians to explore the intricate mechanisms of NF-ΚB P65 activation and its implications in various physiological and pathological processes.
This comprehensive kit includes all the necessary components for a seamless workflow, including pre-coated microplates, assay buffers, detection reagents, and a detailed protocol. The user-friendly nature of this kit allows for effortless implementation, making it suitable for both experienced laboratory professionals and novices alike.
The HUMAN NF-ΚB P65 CLIA Kit offers numerous advantages, such as its high specificity, minimal cross-reactivity, and low background noise. These features ensure the utmost accuracy and reliability in quantifying NF-ΚB P65 levels, enabling researchers to draw meaningful conclusions from their experimental data.
Furthermore, this CLIA kit exhibits excellent precision and reproducibility, minimizing inter-assay and intra-assay variations. Its robust performance guarantees consistent and dependable results, facilitating the progress of scientific investigations and clinical studies.
In summary, the HUMAN NF-ΚB P65 CLIA Kit represents a state-of-the-art solution for the quantification of NF-ΚB P65 in human samples. With its exceptional sensitivity, specificity, and reliability, this kit empowers researchers and clinicians to unravel the intricate role of NF-ΚB P65 in various biological processes, ultimately contributing to advancements in biomedical research and healthcare.
Share
